Explore the vast range of titles available.

Background and Objectives: IgA nephropathy represents the most prevalent form of primary glomerulonephritis around the world, with significant heterogeneity in management strategies and outcomes. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of pharmacological interventions for IgA nephropathy. Materials and Methods: We searched multiple databases through June 2025, identifying randomized controlled trials and observational studies evaluating pharmacological treatments in biopsy-proven IgA nephropathy. Primary outcomes included proteinuria reduction and estimated glomerular filtration ration (eGFR) preservation. Secondary outcomes included hard kidney endpoints and safety parameters. Random-effects meta-analyses were performed with comprehensive risk–benefit assessments. Results: Twenty-five studies were included. B-cell/plasma-cell-targeted therapies showed significant proteinuria reduction (−34.0% [95% CI: −45.7, −22.3%]), complement pathway inhibitors demonstrated superior eGFR preservation (+5.8 mL/min/1.73 m2/year [95% CI: 2.4, 9.2]). Systemic corticosteroids showed observed hard outcome benefits (HR 0.37 [95% CI: 0.26, 0.52]) but highest adverse event risk (RR 3.28 [95% CI: 2.11, 5.09]). Novel agents showed projected favorable effects (B-cell: HR 0.38; complement: HR 0.42) pending validation. Conclusions: Novel targeted therapies, especially B-cell/plasma-cell-targeted agents and complement pathway inhibitors, show promising risk–benefit profiles. However, longer-term data and standardized eGFR slope reporting are needed to confirm these findings compared to other immunosuppressive agents.

Background/Objectives: COVID-19 frequently causes olfactory and gustatory dysfunction, including qualitative disorders like parosmia and phantosmia. These distortions affect quality of life and may result from both peripheral and central neural damage. Despite increasing reports, their prevalence, mechanisms, and risk factors remain unclear. The purpose of this study is to evaluate the clinical characteristics and possible predictors of parosmia and phantosmia associated with COVID-19 in Saudi Arabia. Methods: This cross-sectional study utilized an online questionnaire targeting adults in Saudi Arabia with self-reported new-onset olfactory or gustatory dysfunction after COVID-19. Results: Out of 539 participants, 377 were included for analysis. Females slightly outnumbered males (195, 51.7% vs. 182, 48.3%) with a mean age of 34.5 years (SD = 12.7). Comorbidities were present in 86 (23.3%) participants, predominantly including hypertension (39.5%) and diabetes (30.2%). Sudden smell and taste loss were reported by 277 (73.5%) and 267 (70.8%) participants, respectively. Regional residence was significantly associated with both smell (p < 0.001) and taste loss (p < 0.001). Academic qualification exhibited borderline significance in relation to taste loss (p = 0.049). Logistic regression analysis indicated no significant predictors of dysfunction, with male gender exhibiting an odds ratio of 1.276 for smell (p = 0.301) and an odds ratio of 1.401 for taste (p = 0.144). Over 60% of participants experienced a negative impact on their quality of life. Conclusions: This study demonstrates the prevalence of parosmia and phantosmia in COVID-19 patients in Saudi Arabia, with a significant impact on quality of life. While regional differences and education level exhibited certain associations, no demographic or clinical factors independently predicted dysfunction, highlighting the necessity for additional research into underlying mechanisms and long-term effects.

Introduction: Cerebral palsy (CP) affects motor function development, requiring intensive rehabilitation. Virtual reality (VR) interventions show promise for improving motor learning through immersive, engaging experiences. This systematic review and meta-analysis evaluated VR effectiveness for motor function improvement in children with CP. Methods: Following PRISMA 2020 guidelines, we searched six electronic databases from inception to 15 June 2025. Included studies compared VR interventions versus control conditions in children with CP (ages 4–18 years), measuring motor function outcomes. Sixteen studies (n = 397 participants) met the inclusion criteria for qualitative synthesis. Random-effects models, subgroup analyses, and meta-regression were performed. Evidence certainty was evaluated using GRADE methodology. Results: Five randomized controlled trials with complete extractable data (N = 190 participants, 40 effect sizes) were included in the primary quantitative meta-analysis. The primary meta-analysis demonstrated moderate overall effects favoring VR interventions (standardized mean difference [SMD] = 0.41, 95% CI [0.16, 0.66], p = 0.001; I2 = 74%); however, GRADE quality was rated LOW due to risk of bias and imprecision. Technology type critically moderated outcomes: robotic exoskeleton systems showed large effects (SMD = 1.00, p = 0.002), commercial gaming platforms showed small-to-moderate effects (SMD = 0.38, p = 0.013), while custom VR systems showed no significant benefit (SMD = 0.01, p = 0.905; Q = 29.00, p < 0.001). Age emerged as the strongest moderator: children (<6 years) demonstrated significant benefits (SMD = 0.98, p < 0.001), whereas school-age children (6–12 years) showed no effect (SMD = −0.01, p = 0.903; meta-regression slope = −0.236 per year, p < 0.001). Dose–response was non-linear, with optimal benefits at 30–40 intervention hours and diminishing returns beyond 50 h. VR proved superior to standard care (SMD = 0.83) but not to active intensive therapies (SMD = 0.09). The safety profile was favorable (1.3% adverse event rate, no serious events). No publication bias was detected. Conclusions: VR interventions demonstrated moderate, technology-dependent motor function improvements in children with CP, with benefits concentrated in young children using robotic systems. Evidence certainty is low, requiring further high-quality trials. Implementation should prioritize robotic VR for children with 30–40 h protocols.